Skip to main content

Table 1 Baseline characteristics of the study population

From: Introduction of less invasive surfactant administration (LISA), impact on diagnostic and therapeutic procedures in early life: a historical cohort study

 

LISA (n = 169)

Control (n = 155)

p-value

GA (weeks + days), mean (SD in days)

28 + 0 (14)

28 + 1 (14)

0.52

GA categories

  

0.26

 24–25 + 6 weeks

29 (17.2%)

21 (13.5%)

 

 26–27 + 6 weeks

58 (34.3%)

50 (32.3%)

 

 28–31 + 6 weeks

82 (48.5%)

84 (54.2%)

 

Birth weight (grams), mean (SD)

1092 (341)

1130 (350)

0.33

Birth weight categories

  

0.44

 < 750 g

29 (17.2%)

22 (14.2%)

 

 750 - 999 g

50 (29.6%)

43 (27.7%)

 

 1000 - 1249 g

34 (20.1%)

36 (23.2%)

 

 ≥ 1250 g

56 (33.1%)

54 (34.8%)

 

Male sex

94 (55.6%)

84 (54.2%)

0.80

Antenatal corticosteroids

  

0.82

 None

8 (4.7%)

9 (5.8%)

 

 Not completed

53 (31.4%)

43 (27.7%)

 

 Completed

108 (63.9%)

103 (66.5%)

 

GA (weeks+days) per category of corticosteroids, mean (SD)

 None

27 + 3 (13)

28 + 0 (10)

0.44

 Not completed

28 + 2 (14)

28 + 5 (15)

0.21

 Completed

27 + 6 (15)

27 + 6 (14)

0.83

Apgar, median (IQR)

 1 min

6 (4.0–6.5)

5 (4–7)

0.89

 5 min

7 (6–8)

7 (6–8)

0.70

Umbilical cord pH, median (IQR)

7.30 (7.26–7.34)

7.30 (7.24–7.34)

0.48

Maximal FiO2 before SF, median (IQR)

35 (30–45)

40 (33.75–50)

0.15

Time birth-SF (hours), median (IQR)

2 (1.5–3.75)

2.5 (2–5)

0.001*

  1. GA Gestational age, LISA Less Invasive Surfactant Administration, GA Gestational age